Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD
Objective We aimed to determine the association of statins with progression to a high risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Design This retrospective cohort study of electronic health record data included patients wi...
Saved in:
Main Authors: | Andrew D Schreiner, William P Moran, Jingwen Zhang, Patrick D Mauldin, Justin Marsden, Mulugeta Gebregziabher, Chelsey A Petz, David G Koch, Chloe Bays |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | BMJ Open Gastroenterology |
Online Access: | https://bmjopengastro.bmj.com/content/11/1/e001404.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study.
by: Wenying Guo, et al.
Published: (2024-01-01) -
The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01) -
Adipokines regulate the development and progression of MASLD through organellar oxidative stress
by: Ke Zhao, et al.
Published: (2025-02-01) -
Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort
by: Antonio Liguori, et al.
Published: (2025-01-01) -
Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study
by: Shan Hong, et al.
Published: (2025-01-01)